Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
June 2015, Vol 6, No 5
June 2015, Vol 6, No 5
In the Literature - June 2015
In the Literature
June 2015, Vol 6, No 5
Read Article
Risk Management a Key Challenge in the New Oncology Payment Models
By
Wayne Kuznar
June 2015, Vol 6, No 5
In a decade of provider risk, the CMS Oncology Payment Models are shifting toward risk management as part of the continued evolution toward integrated networks and bundled payments in healthcare.
Read Article
Elotuzumab, First-in-Class Monoclonal Antibody Immunotherapy, Improves Outcomes in Patients with Multiple Myeloma
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Elotzumab’s “double whammy” mechanism of action acts directly on the tumor itself and enhances the activity of natural killer cells to kill the tumor.
Read Article
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma
By
Chase Doyle
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Combination treatment with nivolumab and ipilimumab doubled progression-free survival in patients with advanced melanoma, according to CheckMate 067 investigators.
Read Article
Expert Panel Discusses Quality Measures, Data Collection, and Outcomes in Oncology
By
Wayne Kuznar
June 2015, Vol 6, No 5
Experts at the AVBCC 5th Annual Conference suggested that retrospective analyses of big data should more effectively differentiate between different approaches to cancer care based on care quality and evidence-based, clinically meaningful outcomes. Data silos can help in the short-term to prioritize process measures.
Read Article
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
By
Lisa A. Raedler, PhD, RPh
Drug Updates
June 2015, Vol 6, No 5
Similar to myelofibrosis and essential thrombocythemia, polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm. Polycythemia vera is characterized by the clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Increased red blood cell mass results in the hyperviscosity of the blood, an increased risk for thrombosis, poor quality of life, and a shortened life expectancy.
Read Article
Less Is More in Cancer Survivor Care
By
Rosemary Frei, MSc
Survivorship
,
Policies & Guidelines
June 2015, Vol 6, No 5
Two oncologists from Fox Chase Cancer Center in Philadelphia have added their weight to the growing call for less intensive follow-up of cancer survivors whenever appropriate.
Read Article
Genomic Sequencing for Pancreatic Cancer Still Facing Hurdles
By
Phoebe Starr
Personalized Medicine
June 2015, Vol 6, No 5
Philadelphia, PA—Although whole genomic sequencing can be done on a patient’s tumor, it does not mean that this will translate to a patient’s getting targeted therapy to identified genetic abnormalities, especially if that patient has pancreatic cancer.
Read Article
Biomarker Testing Trends in Europe Linked to Availability of Specific Targeted Cancer Drugs
By
Laura Morgan
Personalized Medicine
June 2015, Vol 6, No 5
Philadelphia, PA—In an era of personalized care, targeted cancer therapies are on the rise and are expected to reach nearly 60% of the global oncology and hematology drug markets by 2017. By testing for genetic biomarkers, physicians can predict patient response to cancer therapy and identify patients who will benefit most from these treatments, thus serving the 2 purposes of increasing the efficiency of treatment decisions and reducing the use of unnecessary drug prescribing and the associated costs.
Read Article
The New PC-SAF Instrument: A Patient-Reported Outcome Tool for Identifying the Symptoms of Pancreatic Cancer
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
June 2015, Vol 6, No 5
Philadelphia, PA—The prognosis for patients with pancreatic cancer, the leading cause of cancer-related deaths in the United States, remains poor. The diagnosis of pancreatic cancer is often delayed to a late stage, which affects impact. Improving the understanding of the early signs and symptoms of this cancer may improve outcomes.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma